v3.25.1
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 13, 2025
Jun. 30, 2024
Document Information [Line Items]      
Entity Central Index Key 0001659617    
Entity Registrant Name Moleculin Biotech, Inc.    
Amendment Flag true    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Document Type 10-K/A    
Amendment Description Moleculin Biotech, Inc. is filing this Amendment No. 2 on Form 10-K/A, or this Amendment No. 2 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, or the Original 10-K, originally filed with the U.S. Securities and Exchange Commission, or SEC, on March 21, 2025, as amended by Amendment No. 1 on Form 10-K/A, or Amendment No. 1, filed with the SEC on April 18, 2025, solely for the purpose of including certain interactive data file tagging omitted from Amendment No. 1.   This Amendment No. 2 amends and restates in their entirety Items 10 through 14 of the Original 10-K and Amendment No. 1. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, this Amendment No. 2 also contains new certifications by the principal executive officer and the principal financial officer as required by Section 302 of the Sarbanes-Oxley Act of 2002. Accordingly, Item 15 of Part IV is amended to include the currently dated certifications of our principal executive officer and principal financial officer as exhibits. Because no financial statements have been included in this Amendment No. 2 and this Amendment No. 2 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. In addition, because no financial statements are included in this Amendment No. 2, new certifications of our principal executive officer and principal financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 are not required to be included with Amendment No. 2.   Except as described above, no other changes have been made to the Original 10-K or Amendment No. 1. The Original 10-K and Amendment No. 1 continue to speak as of the date of such filings, and we have not updated the disclosures contained therein to reflect any events that have occurred as of a date subsequent to the date of the Original 10-K or Amendment No. 1. Accordingly, this Amendment No. 2 should be read in conjunction with the Original 10-K and Amendment No. 1. Defined terms used, but not defined, herein have the meanings ascribed to them in the Original 10-K and Amendment No. 1.   Unless stated otherwise, references in this Amendment No. 1 to “MBI,” “Moleculin,” or “the Company”, “we”, “our” and “us” are used herein to refer to Moleculin Biotech, Inc.    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Document Transition Report false    
Entity File Number 001-37758    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 47-4671997    
Entity Address, Address Line One 5300 Memorial Drive, Suite 950    
Entity Address, City or Town Houston    
Entity Address, State or Province TX    
Entity Address, Postal Zip Code 77007    
City Area Code 713    
Local Phone Number 300-5160    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol MBRX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 9,000,000
Entity Common Stock, Shares Outstanding   14,000,494  
Auditor Name GRANT THORNTON LLP    
Auditor Location Fort Lauderdale, Florida    
Auditor Firm ID 248